Stock VHI VITALHUB CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Vitalhub Corp.

Equities

VHI

CA92847V5018

Market Closed - Toronto S.E.
Other stock markets
 04:00:00 2024-05-28 pm EDT 		5-day change 1st Jan Change
6.95 CAD -0.50% Intraday chart for Vitalhub Corp. -1.42% +70.34%
May. 10 Transcript : Vitalhub Corp., Q1 2024 Earnings Call, May 10, 2024
May. 10 Vitalhub Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by -98% by 2026.
  • The company's profit outlook over the next few years is a strong asset.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 44.84 times its estimated earnings per share for the ongoing year.
  • The company's enterprise value to sales, at 4.29 times its current sales, is high.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

1st Jan change Capi. Investor Rating ESG Refinitiv
VITALHUB CORP. Stock Vitalhub Corp.
+70.34% 259M -
VEEVA SYSTEMS INC. Stock Veeva Systems Inc.
+5.49% 32.82B
C
PRO MEDICUS LIMITED Stock Pro Medicus Limited
+20.93% 7.95B
C-
SECTRA AB Stock Sectra AB
+30.26% 4.39B
B-
EVOLENT HEALTH, INC. Stock Evolent Health, Inc.
-30.09% 2.65B
C-
OMNICELL, INC. Stock Omnicell, Inc.
-13.90% 1.49B
B
VERADIGM INC. Stock Veradigm Inc.
-16.59% 1.48B -
C+
LUNIT INC. Stock Lunit Inc.
-35.41% 1.12B -
SIMULATIONS PLUS, INC. Stock Simulations Plus, Inc.
+11.17% 994M
C
B-SOFT CO.,LTD. Stock B-SOFT Co.,Ltd.
-39.85% 840M -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. VHI Stock
  4. Ratings Vitalhub Corp.